The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | The prognostic value of MRD negativity
Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, briefly discusses the importance of measurable residual disease (MRD) in multiple myeloma patients, and the value of MRD negativity in newly diagnosed, transplant-eligible and ineligible patients. Prof. Cavo also mentions the improved prognosis observed in patients who are MRD negative, and further highlights the importance of sustained MRD negativity in patients with high-risk cytogenetics. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
